Previous 10 | Next 10 |
1.0% Formulation Reached Primary Endpoint with Statistical Significance Full Analysis Identified Additional Efficacy Signals TORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-r...
TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the 7 th Annual Dermatology...
TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company's proposal to harmonize clinical trial designs in the U.S. ...
2023-10-13 08:27:23 ET More on Momentus, Phio Pharmaceuticals, etc. Momentus Inc. (MNTS) Q2 2023 Earnings Call Transcript Wheeler REIT: Gearing Up For Sharemageddon Momentus to provide orbital delivery services for RIDE! Space Momentus prices $5M stock offeri...
2023-10-12 13:26:41 ET More on Femasys, Jaguar Health, etc. Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript LogicMark, Inc. (LGMK) Q2 2023 Earnings Call Transcript Femasys regains Nasdaq compliance Jaguar Health's Napo Pharma gets patent in Japan ...
Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa", or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today a...
TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of th...
2023-10-12 10:00:14 ET More on Health Care Select Sector SPDR BofA reports 10th consecutive week of equity inflows Citi turns cautious on pharmaceuticals and biotech Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further details see...
2023-10-10 09:28:31 ET More on Edesa Biotech Seeking Alpha’s Quant Rating on Edesa Biotech Historical earnings data for Edesa Biotech Financial information for Edesa Biotech For further details see: Edesa Biotech falls after 1-for-7 reverse stock s...
TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA) ("Edesa" or the "Company"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today is announcing that it intends to effect a one-for-seven reverse share split of its com...
News, Short Squeeze, Breakout and More Instantly...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...